European pharmaceutical cannabis product manufacturer SOMAÍ Pharmaceuticals Unipessoal LDA received authorization for its facility in Lisbon, Portugal, from the Portuguese Health Authority INFRAMED.
Why It Matters
This authorization allows the company to produce, import, and export medicinal cannabis products to numerous global markets.
It awards SOMAÍ a GMP Certificate Part I and Part II, enabling it to execute its plan to own distribution channels in Australia and Germany and to establish distribution partnerships in another eight countries while developing a comprehensive brand of medical cannabis products.
The company also announced that it has successfully raised €5 million of new capital to fund its growth plans.
How It All Started